おすすめの製品
由来生物
goat
品質水準
結合体
unconjugated
抗体製品の状態
affinity isolated antibody
抗体製品タイプ
secondary antibodies
クローン
polyclonal
フォーム
lyophilized powder
テクニック
quantitative precipitin assay: suitable
保管温度
2-8°C
ターゲットの翻訳後修飾
unmodified
遺伝子情報
human ... IGK@(50802)
類似した製品をお探しですか？ 訪問 製品比較ガイド
詳細
Anti-Human κ Light Chain (bound and free) antibody is obtained from goat antiserum. Immunospecific purification removes all goat serum proteins and immunoglobulins that do not bind to the κ light chain (bound and free). The antibody preparation is specific for κ light chains when tested against bound and free light chains. The product shows no reaction with bound or free λ light chains.
免疫原
Purified human normal and myeloma κ light chain
アプリケーション
Anti-Human κ Light Chain (Bound and Free)-FITC antibody was used for as secondary antibody in ELISA at a working antibody dilution of 1:200 using maize seed extracts. For ELISA using NSO/1 myeloma cells, HEK293 cells and mouse plasma, antibody concentration of 1-2 μg/ml was used. The antibody was also used to coat the electrode surface in the preparation of antiatrazine immunosensor.
Anti-Human Kappa Light Chain (Bound and Free) antibody produced in goat has been used in western blotting.
物理的形状
凍結乾燥品(pH 7.2, 0.01 Mリン酸ナトリウム, 0.015M塩化ナトリウム)。
再構成
0.135 M塩化ナトリウムで再構成して下さい。
免責事項
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
適切な製品が見つかりませんか。
製品選択ツール.をお試しください
この製品を見ている人はこちらもチェック
Characterization of immunological interactions at an immunoelectrode by scanning electron microscopy
Ambrosi A et al
Electroanalysis, 19, 244-252 (2007)
Yvonne J Rosenberg et al.
PloS one, 11(3), e0152760-e0152760 (2016-04-01)
Intravascular delivery of broadly neutralizing antibodies (bnAbs) has shown promise for prevention and treatment of HIV infection. However, multiple IV administrations in geographic locations with poor accessibility to medical care have practical limitations. We have assessed the efficacy of plant-derived
Yvonne Rosenberg et al.
PloS one, 8(3), e58724-e58724 (2013-03-28)
Passive immunotherapy using anti-HIV broadly neutralizing monoclonal antibodies (mAbs) has shown promise as an HIV treatment, reducing mother-to-child-transmission (MTCT) of simian/human immunodeficiency virus (SHIV) in non-human primates and decreasing viral rebound in patients who ceased receiving anti-viral drugs. In addition
Ruben J Boado et al.
Biotechnology and bioengineering, 96(2), 381-391 (2006-08-29)
A murine monoclonal antibody (MAb) to the human insulin receptor (HIR) has been engineered for use as a brain drug delivery system for transport across the human blood-brain barrier (BBB). The HIRMAb was humanized by complementarity determining region (CDR) grafting
S M Chamow et al.
Journal of immunology (Baltimore, Md. : 1950), 153(9), 4268-4280 (1994-11-01)
HIV infection depletes the immune system of the coordinating functions of CD4+ T cells and APCs, whereas the population of CD8+ CTLs remains largely intact: functional but undirected. We have developed a humanized bispecific immunoadhesin-antibody (BIA) that redirects these remaining
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）